Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27879786 | 0.91 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL29101322 | 0.89 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL9670017 | 0.87 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL10697841 | 0.87 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2242410 | 0.86 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL516166 | 0.84 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL95904 | 0.83 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2009955 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL8099831 | 0.81 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL15285199 | 0.80 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6312953-B1 | MODIFIED OLIGONUCLEOTIDE COMPLEMENTARY TO A TARGET SEQUENCE AND HAVING AT LEAST TWO CROSSLINKING AGENTS COVALENTLY ATTATCHED; GENE EXPRESSION INHIBITION; DNA SEQUENCING; GENETIC MAPPING | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |